
Arrowhead Pharmaceuticals, Inc.
ARWRHealthcare|Biotechnology|US
$58.16
+0.70 (+1.22%)
Tangible Book / Share
$3.21
Cash / Share
$11.17
Financials
Financial Snapshot
Market Cap
$8.22B
Enterprise Value
$9.02B
Revenue (TTM)
$669.5M
Net Income (TTM)
-$320.0M
Cash & Investments
$1.60B
Net Cash
$737.9M
Free Cash Flow (TTM)
-$75.1M
Operating CF (TTM)
-$59.1M
Debt/Equity
1.86
Cash Runway & Burn Rate
Cash on Hand
$1.60B
Quarterly Burn
$14.8M
Monthly Burn
$4.9M
Est. Runway
~108.5 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $85.4M | $65.6M | $76.5M | $258.7M | $315.5M | $367.8M | $376.4M | $403.6M | $681.0M | $919.4M | $1.60B | |
| Operating Cash Flow | -$64.4M | -$23.9M | -$47.2M | $173.0M | -$95.8M | $171.3M | -$136.1M | -$153.9M | -$462.9M | $179.6M | -$59.1M | |
| Free Cash Flow | -$68.3M | -$31.9M | -$48.6M | $161.0M | -$107.8M | $147.7M | -$188.9M | -$330.6M | -$604.3M | $156.9M | -$75.1M | |
| Capital Expenditure | -$3.9M | -$7.9M | -$1.4M | -$12.0M | -$12.0M | -$23.6M | -$52.8M | -$176.7M | -$141.5M | -$22.7M | -$16.1M | |
| Financing Cash Flow | $55.1M | $12.1M | $60.0M | $66.4M | $257.9M | $11.3M | $65.2M | $253.1M | $870.5M | $74.0M | $784.2M |
R&D Spending
R&D (TTM)
$723.4M
R&D Intensity
108.0%
R&D Growth vs Prior
+19.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $158.3K | $31.4M | $16.1M | $168.8M | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M | $669.5M | |
| R&D Expense | $41.5M | $46.3M | $48.3M | $76.6M | $123.5M | $206.3M | $288.5M | $342.3M | $489.2M | $607.2M | $723.4M | |
| R&D % of Revenue | 26181.8% | 147.3% | 299.2% | 45.4% | 140.4% | 149.2% | 118.6% | 142.2% | 13776.9% | 73.2% | 108.0% | |
| SG&A | $23.6M | $17.5M | $19.1M | $26.5M | $52.3M | $81.0M | $124.4M | $90.9M | $96.8M | $121.9M | $171.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $158.3K | $31.4M | $16.1M | $168.8M | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M | $669.5M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.4M | $12.5M | $18.6M | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $138.3M | $232.8M | $228.2M | -$15.0M | $829.4M | $669.5M | |
| R&D | $41.5M | $46.3M | $48.3M | $76.6M | $123.5M | $206.3M | $288.5M | $342.3M | $489.2M | $607.2M | $723.4M | |
| SG&A | $23.6M | $17.5M | $19.1M | $26.5M | $52.3M | $81.0M | $124.4M | $90.9M | $96.8M | $121.9M | $171.1M | |
| Operating Income | -$81.7M | -$37.0M | -$55.9M | $61.2M | -$93.2M | -$149.0M | -$178.5M | -$205.0M | -$601.1M | $98.3M | -$226.4M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $18.3M | $32.4M | $89.4M | $92.6M | |
| Pretax Income | -$81.7M | -$34.4M | -$54.4M | $68.1M | -$84.6M | -$140.8M | -$172.7M | -$206.5M | -$612.5M | $51.5M | -$252.1M | |
| Net Income | -$81.7M | -$34.4M | -$54.5M | $68.0M | -$84.6M | -$140.8M | -$176.1M | -$205.3M | -$599.5M | -$1.6M | -$320.0M | |
| EPS (Diluted) | -1.34 | -0.47 | -0.65 | 0.69 | -0.84 | -1.36 | -1.67 | -1.92 | -5.00 | -0.01 | -2.24 | |
| EBITDA | -$76.4M | -$32.3M | -$51.2M | $65.6M | -$87.2M | -$132.6M | -$162.3M | -$175.7M | -$561.5M | $164.8M | -$133.7M | |
| Shares Out. (M) | 61.05 | 73.90 | 83.64 | 98.61 | 100.72 | 103.74 | 105.43 | 106.75 | 119.78 | 133.76 | 143.38 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.4M | $24.8M | $30.1M | $221.8M | $143.6M | $184.4M | $108.0M | $110.9M | $102.7M | $226.5M | $54.8M | |
| Short-Term Investments | $0.00 | $40.8M | $46.4M | $36.9M | $171.9M | $183.4M | $268.4M | $292.7M | $578.3M | $692.8M | $1.55B | |
| Total Current Assets | $90.5M | $67.9M | $78.8M | $265.2M | $322.4M | $384.6M | $405.3M | $419.5M | $695.5M | $950.6M | $1.67B | |
| Total Assets | $128.2M | $104.0M | $111.6M | $349.8M | $522.5M | $710.1M | $691.9M | $765.6M | $1.14B | $1.39B | $2.11B | |
| Total Current Liabilities | $25.6M | $18.7M | $12.4M | $97.1M | $40.7M | $146.5M | $138.8M | $105.5M | $103.2M | $195.5M | $283.3M | |
| Long-Term Debt | $2.5M | $2.3M | $2.1M | $0.00 | $0.00 | $0.00 | $0.00 | $268.3M | $734.5M | $214.9M | $824.1M | |
| Total Liabilities | $33.2M | $23.2M | $16.4M | $105.8M | $60.7M | $301.3M | $273.6M | $478.4M | $948.7M | $881.9M | $1.65B | |
| Stockholders' Equity | $95.6M | $81.4M | $95.8M | $244.6M | $461.8M | $408.8M | $398.5M | $271.3M | $185.4M | $466.1M | $465.5M | |
| Retained Earnings | -$398.4M | -$432.8M | -$487.3M | -$419.3M | -$503.8M | -$644.7M | -$820.8M | -$1.03B | -$1.63B | -$1.63B | -$1.92B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$64.4M | -$23.9M | -$47.2M | $173.0M | -$95.8M | $171.3M | -$136.1M | -$153.9M | -$462.9M | $179.6M | -$59.1M | |
| Capital Expenditure | -$3.9M | -$7.9M | -$1.4M | -$12.0M | -$12.0M | -$23.6M | -$52.8M | -$176.7M | -$141.5M | -$22.7M | -$16.1M | |
| Free Cash Flow | -$68.3M | -$31.9M | -$48.6M | $161.0M | -$107.8M | $147.7M | -$188.9M | -$330.6M | -$604.3M | $156.9M | -$75.1M | |
| Investing Cash Flow | $13.4M | -$48.6M | -$7.4M | -$47.7M | -$240.8M | -$141.7M | -$5.4M | -$96.2M | -$420.1M | -$129.3M | -$801.7M | |
| Financing Cash Flow | $55.1M | $12.1M | $60.0M | $66.4M | $257.9M | $11.3M | $65.2M | $253.1M | $870.5M | $74.0M | $784.2M | |
| Issuance of Stock | $52.2M | $12.4M | $56.6M | $60.5M | $250.5M | $0.00 | $5.2M | $3.1M | $431.7M | $270.4M | $303.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$217.5K | -$197.8K | -$208.5K | -$2.4M | $0.00 | $0.00 | $0.00 | $0.00 | $392.0M | -$191.4M | $1.19B | |
| Stock Based Comp. | $11.6M | $7.9M | $8.5M | $12.4M | $43.4M | $76.7M | $120.9M | $78.1M | $74.0M | $63.4M | $70.0M | |
| Net Change in Cash | $4.2M | -$60.5M | $5.3M | $191.7M | -$78.2M | $40.9M | -$76.4M | $2.9M | -$8.2M | $123.9M | -$75.0M |
Dilution Tracker
Shares outstanding grew 32.8% over 5 years — significant dilution
Shares Outstanding
141M
5-Year Share Growth
+32.8%
Stock Issuance (TTM)
$303.9M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 61.05 | 73.90 | 83.64 | 98.61 | 100.72 | 103.74 | 105.43 | 106.75 | 119.78 | 133.76 | 143.38 | |
| Change vs Prior % | — | 21.0% | 13.2% | 17.9% | 2.1% | 3.0% | 1.6% | 1.3% | 12.2% | 11.7% | 7.2% | |
| Stock Issuance | $52.2M | $12.4M | $56.6M | $60.5M | $250.5M | $0.00 | $5.2M | $3.1M | $431.7M | $270.4M | $303.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $11.6M | $7.9M | $8.5M | $12.4M | $43.4M | $76.7M | $120.9M | $78.1M | $74.0M | $63.4M | $70.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 95.7% | 94.8% | -423.7% | 100.0% | 100.0% | |
| Operating Margin % | -51627.1% | -117.8% | -346.5% | 36.3% | -105.9% | -107.8% | -73.4% | -85.2% | -16927.1% | 11.9% | -33.8% | |
| Net Margin % | -51614.6% | -109.5% | -337.3% | 40.3% | -96.1% | -101.9% | -72.4% | -85.3% | -16882.4% | -0.2% | -47.8% | |
| EBITDA Margin % | -48272.9% | -102.9% | -317.4% | 38.9% | -99.1% | -95.9% | -66.7% | -73.0% | -15812.8% | 19.9% | -20.0% | |
| FCF Margin % | -43129.2% | -101.4% | -301.3% | 95.4% | -122.5% | 106.8% | -77.7% | -137.3% | -17018.3% | 18.9% | -11.2% | |
| ROE % | -85.5% | -42.2% | -56.8% | 27.8% | -18.3% | -34.5% | -44.2% | -75.7% | -323.3% | -0.3% | -60.5% | |
| ROA % | -63.8% | -33.1% | -48.8% | 19.4% | -16.2% | -19.8% | -25.4% | -26.8% | -52.6% | -0.1% | -15.1% | |
| ROIC % | -79.6% | -43.3% | -56.2% | 24.1% | -19.3% | -26.3% | -32.1% | -30.6% | -57.4% | 4.6% | -12.1% | |
| R&D / Revenue % | 26181.8% | 147.3% | 299.2% | 45.4% | 140.4% | 149.2% | 118.6% | 142.2% | 13776.9% | 73.2% | 108.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -58.6% | 19736.5% | -48.6% | 945.7% | -47.9% | 57.2% | 75.9% | -1.0% | -98.5% | 23258.2% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 68.4% | -2.0% | -106.6% | 5613.5% | |
| Operating Income | 14.8% | 54.7% | -51.2% | 209.4% | -252.2% | -60.0% | -19.8% | -14.8% | -193.2% | 116.4% | |
| Net Income | 11.1% | 57.9% | -58.4% | 224.8% | -224.4% | -66.6% | -25.0% | -16.6% | -192.0% | 99.7% | |
| EPS (Diluted) | 16.3% | 64.9% | -38.3% | 206.2% | -221.7% | -61.9% | -22.8% | -15.0% | -160.4% | 99.8% | |
| Operating Cash Flow | 1.9% | 62.8% | -97.3% | 466.4% | -155.4% | 278.8% | -179.5% | -13.0% | -200.8% | 138.8% | |
| Free Cash Flow | -0.9% | 53.3% | -52.7% | 431.0% | -166.9% | 237.1% | -227.9% | -75.0% | -82.8% | 126.0% | |
| R&D Expense | -12.3% | 11.6% | 4.4% | 58.7% | 61.2% | 67.0% | 39.8% | 18.7% | 42.9% | 24.1% | |
| SG&A Expense | -32.0% | -26.0% | 9.3% | 39.1% | 97.0% | 54.9% | 53.7% | -26.9% | 6.5% | 25.9% | |
| Total Assets | -3.1% | -18.8% | 7.3% | 213.5% | 49.4% | 35.9% | -2.6% | 10.6% | 48.9% | 21.5% | |
| Book Value / Share | -18.5% | -29.0% | 3.0% | 128.3% | 76.3% | -14.0% | 0.7% | -32.2% | -40.7% | 136.0% | |
| Debt | 259.7% | -7.1% | -8.2% | -100.0% | 0.0% | 20.8% | 219.3% | 370.1% | 122.1% | -57.0% | |
| Diluted Shares | 6.4% | 21.0% | 13.2% | 17.9% | 2.1% | 3.0% | 1.6% | 1.3% | 12.2% | 11.7% |
Valuation
P/E (TTM)At Loss
P/S12.27
10Y Low / Med / High5.56 / 46.84 / 2831.10
P/B17.91
10Y Low / Med / High3.89 / 10.57 / 16.77
EV/EBITDAAt Loss
EV/Revenue13.48
10Y Low / Med / High5.73 / 45.69 / 2309.17
P/FCFAt Loss
10Y Low / Med / High16.42 / 29.41 / 43.84
Intrinsic Value Models (per share)
Tangible Book / Share
$3.21
Net Current Assets / Share
$0.18
Cash / Share
$11.17
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -5.49 | -9.21 | -29.55 | 39.14 | -51.26 | -45.90 | -19.79 | -13.99 | -3.87 | -2827.05 | -25.96 | |
| P/S Ratio | 2831.10 | 10.08 | 99.53 | 15.67 | 49.29 | 46.84 | 14.33 | 11.92 | 653.40 | 5.56 | 12.27 | |
| P/B Ratio | 4.69 | 3.89 | 16.77 | 10.81 | 9.39 | 15.84 | 8.74 | 10.57 | 12.51 | 9.90 | 17.91 | |
| EV/EBITDA | -4.78 | -9.11 | -30.82 | 36.92 | -48.32 | -47.65 | -21.31 | -17.88 | -5.47 | 28.84 | -67.52 | |
| EV/Revenue | 2309.17 | 9.37 | 97.81 | 14.36 | 47.90 | 45.69 | 14.22 | 13.05 | 864.39 | 5.73 | 13.48 |
Analyst Estimates & Quality
Altman Z-Score
2.58
Grey Zone
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $330.1M | $666.1M | $1.15B |
| Net Income | -$710.2M | -$461.7M | -$178.3M |
| EPS | $-4.86 | $-2.81 | $-0.74 |
| # Analysts (EPS) | 13 | 8 | 5 |